Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mariel Therapeutics has entered into a definitive agreement to acquire Stryker Corporation's (SYK) Bone Morphogenetic Protein-7 (BMP-7) assets for the potential treatment of osteoarthritis (OA), chronic kidney disease (CKD) and other organ fibrosis conditions, lupus, and obesity.
Subscribe to our email newsletter
Under the terms of the agreement, Mariel acquired the rights to over 450 issued and pending patents, Stryker’s BMP-7-related clinical and research data, and the associated biologic materials.
Stryker will have a right of first negotiation for commercial rights in the area of osteoarthritis. Financial terms of the transaction were not disclosed.
Human recombinant BMP-7 has previously been used in reconstructive bone applications in over 40,000 patients.
Previous Phase I and Phase IIa trials have been completed in osteoarthritis. Mariel intends to pursue a Phase IIb/III clinical trial for osteoarthritis (OA) and Phase I trials for chronic kidney disease (CKD) and Alport’s disease, a genetic kidney fibrosis disease.
Mariel is a clinical stage biopharmaceutical company focused on the clinical application of Bone Morphogenetic Protein-7 (BMP-7) in osteoarthritis (OA), chronic kidney disease (CKD), and Alport’s Syndrome.